Subscribe
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma
Web Exclusives
Pembrolizumab With Chemotherapy for Some Endometrial Carcinomas Gets Green Light
FDA Approvals, News & Updates
Web Exclusives
— June 18, 2024
FDA officials approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma efficacy of this treatment was evaluated in KEYNOTE-868/NRG-GY018.
Read Article
Addressing Cancer Health Disparities: The No One Left Alone Initiative
By
Rohan Nathwani
;
Arva Patel
;
Warner Kornberg
;
Asutosh Gor, MD
;
Sashi Naidu, MD
;
Viral Rabara, MD
;
Niyati Nathwani, MD
;
Kashyap Patel, MD
Health Disparities
Web Exclusives
— May 14, 2024
Despite ranking among the top 6 wealthiest economies in the world per capita, the United States still has sizable health disparities among its citizens, which are rooted in social, economic, and environmental factors. Place of birth is more strongly associated with life expectancy than race or genetics.
Read Article
Navigating the Complex Landscape of Oral Cancer Medication
Oral Oncolytics
Web Exclusives
— April 15, 2024
Recognizing the complexities of treatment with oral medications is an important step toward successful outcomes.
Read Article
Tornado Sweeps Through Pfizer’s Storage and Manufacturing Facility
FDA Approvals, News & Updates
Web Exclusives
— August 7, 2023
On July 19, 2023, an EF3 tornado touched down in Rocky Mount, NC, badly damaging a Pfizer drug manufacturing facility that is responsible for producing nearly 25% of Pfizer’s sterile injectable medicines used in US hospitals.
Read Article
Results from Phase 3 Trial Show Similar Efficacy and Safety Outcomes with CT-P16 versus Bevacizumab in Patients with NSCLC
Biosimilars
Web Exclusives
— January 31, 2023
One-year follow-up data from a phase 3 study found similar duration of response, time to progression (TTP), and survival rates with the biosimilar candidate CT-P16 compared with its reference drug, bevacizumab (Avastin), in the first-line treatment of patients with metastatic or recurrent nonsquamous non–small-cell lung cancer (NSCLC).
Read Article
A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients
JCP Special Report
Web Exclusives
— December 5, 2022
In an interview, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.
Read Article
NaF PET Imaging Demonstrates Increased Sensitivity for New Lesion Detection for Patients with Metastatic Prostate Cancer
Prostate Cancer Diagnostics
Web Exclusives
— October 19, 2021
NaF PET imaging study demonstrates an increased sensitivity over Tc99m-MDP bone scans for new lesion detection in patients with stable metastatic prostate cancer.
Read Article
Diagnostic Capability in Relapsed Prostate Cancer Improved with ¹⁸F-DCFPyL PET/CT Imaging
Prostate Cancer Diagnostics
Web Exclusives
— October 19, 2021
Recently released analysis of
18
F-DCFPyL PET/CT accuracy demonstrated improved diagnostic capability in men with biochemical recurrence of prostate cancer.
Read Article
Recent Study Results Finds ¹⁸F-Fluciclovine PET/CT Alters Recurrent Prostate Cancer Management
Prostate Cancer Diagnostics
Web Exclusives
— October 19, 2021
Salvage radiotherapy decisions for patients with recurrent prostate cancer after prostatectomy change after
18
F-fluciclovine PET/CT reveals higher positive findings than conventional imaging.
Read Article
Multicenter International Prospective Trial on Gallium-68 PSMA PET/CT Imaging Confirms Accuracy in Detecting Prostate Cancer Recurrence
Prostate Cancer Diagnostics
Web Exclusives
— October 19, 2021
Gallium-68 PSMA PET/CT imaging in patients with early relapsed prostate cancer confirms the reliability of this imaging modality in local and metastatic lesion detection.
Read Article
Page 4 of 14
1
2
3
4
5
6
7
Top Trending Articles
1.
Gaps in Biomarker Testing and Targeted Therapy for Gastric Cancer
Ashley Gamble, PhD
,
John Perez, MBA, MSDS
2.
Guiding Patients Through Policy Shifts and Enrollment Opportunities in 2026
Meg Barbor, MPH
3.
ACCC Federal Policy Update Highlights Key Risks and Opportunities for Oncology Practices in 2026
Meg Barbor, MPH
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma